Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations
Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.
Recent Videos
Related Content
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
November 12th 2024Article
In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read More
Uproleselan With Chemo Fails to Improve EFS in Older Patients With AML
November 2nd 2024Article
A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.
Read More
